Tag: Veloxis
OSE Immuno’s US partner, Veloxis, obtains fast track status for FR104
Veloxis plans to develop FR104 in order to provide a new therapeutic option in the prophylaxis of organ rejection in patients who have received a solid organ transplant. Less than…
OSE Immunotherapeutics is pleased to announce FDA Fast Track Designation for CD28 antagonist VEL-101/FR104, granted by Veloxis Pharmaceuticals, Inc., its partner in transplantation – 02/17/2022 18:00
Nantes, France – February 17, 2022, 6:00 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that Veloxis Pharmaceuticals, Inc., a subsidiary of Asahi Kasei, has obtained “Fast Track”…
OSE Immuno: FDA green light for Veloxis Pharmaceuticals
(CercleFinance.com) – OSE Immunotherapeutics announces that the United States Food & Drug Administration (FDA) has accepted the Investigational New Drug (IND) application formulated by Veloxis Pharmaceuticals for a clinical trial…